Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 13/20 | 0.55 |
| ▸ | HTR2A | P28223 | 12/20 | 0.55 |
| ▸ | DRD2 | P14416 | 8/20 | 0.55 |
| ▸ | HTR7 | P34969 | 1/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 11/20 | 0.51 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6107367 | 0.91 | ABCB1 (0.58) | HTR1AHTR2ADRD2HTR7KCNH2 | |
| SCHEMBL6108816 | 0.87 | HTR1A (0.61) | HTR1AHTR2ADRD2HTR7KCNH2 | |
| SCHEMBL6105815 | 0.87 | HTR1A (0.55) | HTR1AHTR2ADRD2HTR7KCNH2 | |
| SCHEMBL6105622 | 0.86 | HTR1A (0.62) | HTR1AHTR2ADRD2HTR7KCNH2 | |
| SCHEMBL6104305 | 0.85 | HTR1A (0.54) | HTR1AHTR2ADRD2HTR7KCNH2 | |
| SCHEMBL6107779 | 0.85 | HTR1A (0.63) | HTR1AHTR2ADRD2HTR7KCNH2 | |
| SCHEMBL6107510 | 0.85 | HTR1A (0.63) | HTR1AHTR2ADRD2HTR7KCNH2 | |
| SCHEMBL6106641 | 0.84 | HCAR2 (0.51) | HTR1AHTR2ADRD2HTR7 | |
| SCHEMBL6106916 | 0.84 | HTR1A (0.61) | HTR1AHTR2ADRD2HTR7KCNH2 | |
| SCHEMBL6105081 | 0.83 | HTR1A (0.59) | HTR1AHTR2ADRD2HTR7KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7101886-B2 | Phenylalkyl and pyridylalkyl piperazine derivatives | WARNER LAMBERT COMPANY (US) | 2006-09-05 | — | — | US | disclosed |
| US-20040186108-A1 | Phenylalkyl and pyridylalkyl piperazine derivatives | CHO STEPHEN SUNG YONG (US) | 2004-09-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040186108-A1 | Phenylalkyl and pyridylalkyl piperazine derivatives | CNR1, CNR2, PMP22 | HTR1A 23/4885HTR2A 61/4885DRD2 45/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.